Advertisement

Clinical Drug Investigation

, Volume 15, Issue 6, pp 483–489 | Cite as

Effect of Levamisole on the Immune Response of Patients with Schistosomiasis after Treatment with Praziquantel

  • J. R. Snyman
  • De K. Sommers
Clinical Pharmacodynamic

Summary

Successful therapy with praziquantel in schistosomiasis is dependent on a normal host immune system, i.e. the recognition of parasite antigen, to be effective in eradicating the parasite. Levamisole, a nonspecific immunomodulator, has been hypothesised to normalise deficient cell-mediated immunity. The aim of this study was to investigate the effect of levamisole on the immune response seen after presumed curative doses of praziquantel. After ethical approval, 29 male volunteers infected with Schistosoma haematobium were recruited and randomised to receive orally either (a) levamisole 5 mg/kg for 2 consecutive days, plus praziquantel 40 mg/kg as a single dose, (b) levamisole 5mg/kg for 2 days, or (c) praziquantel 40mg/kg as a single dose. Blood samples were collected on day 0 and again 3 months later for differential counts and specific IgG and IgE to whole-worm-antigen, as well as for the detection of eosinophil cationic protein (ECP). Levamisole treatment alone resulted in a significant drop in circulating eosinophil counts, i.e. a median (95% confidence interval) drop of 6.0 (1;7)%. Eosinophil counts did not change significantly after praziquantel therapy alone. ECP values were significantly reduced with levamisole alone and praziquantel alone, i.e. respective median (95% confidence interval) drops of 33.58 (18.94; 55.9) and 16.54 (3.6; 33.5) μg/L (p < 0.05). The group receiving combination therapy demonstrated significant increases in specific IgG values (p = 0.02) with no decline in ECP levels and eosinophil counts compared with baseline values. Levamisole alone had no effect on egg counts.

In conclusion, levamisole inhibited circulating eosinophils and eosinophil activation when given alone, but caused immune stimulation when combined with praziquantel. The exact mechanism of action still needs to be determined.

Keywords

Adis International Limited Schistosomiasis Levamisole Eosinophil Count Praziquantel 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Van Wauwe J, Janssen PAJ. Review article on the biochemical mode of action of levamisole: an update. Int J Immunopharm 1991; 13: 3–9CrossRefGoogle Scholar
  2. 2.
    Symoens J, Rosenthal M. Levamisole in the modulation of the immune response: the current experimental and clinical state. J Reticuloend Soc 1977; 21: 175–221Google Scholar
  3. 3.
    Renoux G. The general immunopharmacology of levamisole. Drugs 1980; 19: 89–99CrossRefGoogle Scholar
  4. 4.
    Makled MKh, El Gindy MS, Abdel Wahab MF, et al. Parasitological and clinical effect of levamisole in intestinal bilharziasis. J Egypt Soc Parasitai 1985; 15: 299–303Google Scholar
  5. 5.
    El Helaly S, Gomaa A, Makled MKh, et al. Prognostic value of levamisole on bilharzia patients with bronchial asthma. J Egypt Soc Parasitai 1988; 18: 397–402Google Scholar
  6. 6.
    Sabah AA, Fletcher C, Webbe G, et al. Schistosoma mansoni:. reduced efficacy of chemotherapy in infected T-cell deprived mice. Exp Parasitai 1985; 60: 348–54CrossRefGoogle Scholar
  7. 7.
    Brindley PJ, Sher A. The chemotherapeutic effect of praziquantel against Schistosoma namsoni is dependent on host antibody response. J Immunol 1987; 139: 215–20PubMedGoogle Scholar
  8. 8.
    Doenhoff MJ, Sabah AA, Fletcher C, et al. Evidence for an immune dependent action of praziquantel on Schistosoma mansoni in mice. Trans R Soc Trop Med Hyg 1987; 81: 947–51PubMedCrossRefGoogle Scholar
  9. 9.
    Groll E. Praziquantel. Adv Pharmacol Chemother 1984; 20: 219–35PubMedCrossRefGoogle Scholar
  10. 10.
    Flisser A, Mclaren DJ. Effect of praziquantel treatment on lung stage larvae of Schistosomu mansoni in vivo. Parasitology 1989; 98: 203–11PubMedCrossRefGoogle Scholar
  11. 11.
    Piper KP, Mott RF, Hockley DJ, et al. Schistosoma mansoni: Larval damage and the role of effector cell(s) in the synergy between vaccine immunity and praziquantel treatment. Parasitology 1991; 103: 207–24PubMedCrossRefGoogle Scholar
  12. 12.
    Dunne DW, Butterworth AE, Fulford AJC, et al. Immunity after treatment of human schistosomiasis: association between IgE antibodies to adult worm antigens and resistance to reinfection. Eur J Immunol 1992; 22: 1483–91PubMedCrossRefGoogle Scholar
  13. 13.
    Woolhouse MEJ, Taylor P, Matanhire D, et al. Acquired immunity and epidemiology of Schistosoma haematobium. Nature 1991; 351: 757–9PubMedCrossRefGoogle Scholar
  14. 14.
    Hagan P, Wilkins HA, Blumenthal UJ, et al. Eosinophilia and resistance to Schistosomu haematobium in man. Parasite Immunol 1985; 7: 625–32PubMedCrossRefGoogle Scholar
  15. 15.
    Rihet P, Demeure CE, Bourgois A, et al. Evidence for an association between human resistance to Schistosoma mansoni and high anti-larval IgE levels. Eur J Immunol 1991; 21: 2679–86PubMedCrossRefGoogle Scholar
  16. 16.
    Wilkins HA, Moore PJ. Comparative trials of regimens for the treatment of urinary schistosomiasis in The Gambia. J Trop Med Hyg 1987; 90: 83–92PubMedGoogle Scholar
  17. 17.
    Shaw MK, Erasmus DA. Schistosoma mansoni structural damage and tegumental repair after in. vivo treatment with praziquantel. Parasitology 1987; 94: 243–54PubMedCrossRefGoogle Scholar
  18. 18.
    Butterworth AE, Dalton PR, Dunne DW, et al. Immunity after treatment of human schitosomiasis mansoni. I. Study design, pretreatment observations and the results of treatment. Trans R Soc Trop Med Hyg 1984; 78: 108–23PubMedCrossRefGoogle Scholar
  19. 19.
    Kimani G, Chunge CN, Butterworth AE, et al. Eosinophilia and eosinophil helminthotoxicity in patients treated for Schistosoma mansoni infections. Trans R Soc Trop Med Hyg 1991; 85: 489–92PubMedCrossRefGoogle Scholar
  20. 20.
    Venge P. Serum measurements of eosinophil cationic protein (ECP) in bronchial asthma. Clin Exp Allergy 1993; 23(S2): 1–5CrossRefGoogle Scholar
  21. 21.
    Van Dam GJ, Stelma FF, Greyseels B, et al. Antibody response patterns against Schistosoma mansoni in a recently exposed community in Senegal. J Infect Dis 1996; 173: 1231–41Google Scholar
  22. 22.
    Kurakata S, Kitamura K. Suppressor cells in levamisole-treated mice: a possible role of T-cell-mediated feedback suppression in the drug-induced suppression of the humeral immune response. Immunopharmacology 1983; 6: 279–87PubMedCrossRefGoogle Scholar
  23. 23.
    Snyman JR, Sommers De K. Levamisole augments roxatidine's immune modulatory effects in the graft-versus-host reaction (GVHR). Immunopharmacology 1992; 23: 125–30PubMedCrossRefGoogle Scholar
  24. 24.
    Snyman JR, Sommers De K. Levamisole's effect on the cutaneous hypersensitivity reaction and eosinophil function in patients allergic to grass pollen. Med Sci Res 1998. In pressGoogle Scholar
  25. 25.
    Olds GR, Ellner JJ. Modulation of macrophage activation and resistance by suppressor T-lymphocytes in chronic Schistosoma mansoni infection. J Immunopharmacology 1984; 133: 2720–4Google Scholar
  26. 26.
    Ramalho-Pinto FJ, Smithers SR. Suppressor T-cells in the specific control of the carrier response to Schistosomula in mice infected with Schistosoma mansoni. Parasite Immunol 1981; 3: 219–26PubMedCrossRefGoogle Scholar
  27. 27.
    Snyman JR, Sommers De K, Steinmann MA, et al. Effects of calcitriol on eosinophil activity and antibody responses in patients with schistosomiasis. Eur J Clin Pharmacol 1997; 52: 277–80PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1998

Authors and Affiliations

  1. 1.Department of Pharmacology, Faculty of MedicineUniversity of PretoriaPretoriaSouth Africa

Personalised recommendations